Advanced Search
JIANG Hongqing, LIU Ping, LIU Zhihui. Comparison of Survival and Postoperative Complication of Stage Ⅰb2-Ⅱa2 Cervical Cancer Patients Among Three Kinds of Therapeutic Regimens[J]. Cancer Research on Prevention and Treatment, 2019, 46(9): 825-828. DOI: 10.3971/j.issn.1000-8578.2019.18.0605
Citation: JIANG Hongqing, LIU Ping, LIU Zhihui. Comparison of Survival and Postoperative Complication of Stage Ⅰb2-Ⅱa2 Cervical Cancer Patients Among Three Kinds of Therapeutic Regimens[J]. Cancer Research on Prevention and Treatment, 2019, 46(9): 825-828. DOI: 10.3971/j.issn.1000-8578.2019.18.0605

Comparison of Survival and Postoperative Complication of Stage Ⅰb2-Ⅱa2 Cervical Cancer Patients Among Three Kinds of Therapeutic Regimens

More Information
  • Received Date: November 18, 2018
  • Revised Date: May 04, 2019
  • Available Online: January 12, 2024
  • Objective 

    To investigate the effects of radical surgery, neoadjuvant chemotherapy combined with radical surgery and concurrent chemoradiotherapy combined with radical surgery on the survival and postoperative complications of patients with stageⅠb2 andⅡa2 cervical cancer.

    Methods 

    We retrospectively analyzed the clinical data of 140 patients with stageⅠb2 and Ⅱa2 cervical cancer, 48 patients were treated with radical surgery alone (group A), 59 patients were treated with neoadjuvant chemotherapy combined with radical surgery (group B) and 33 patients were treated with concurrent chemoradiotherapy combined with radical surgery (group C). The intraoperative and postoperative clinical indicators, local invasion and lymph node metastasis rate, postoperative complication rate, median overall survival, and 1-, 2-, and 3-year survival rates were compared among three groups.

    Results 

    There was no significant difference in the time of surgery and total hospital stay among the three groups (P > 0.05). The bleeding volume, postoperative vessel and muscle invasion rate and lymph node metastasis rate in group C were significantly lower than those in group A and B (P < 0.05). Postoperative neurological invasion rate, postoperative complication rate, median overall survival and postoperative 1-, 2- and 3-year survival rates showed no significant difference among three groups (P > 0.05). Group B was divided into radiotherapy group (n=28), chemotherapy group (n=13) and chemoradiotherapy group (n=18) according to preoperative treatment. The 3-year survival rate of radiotherapy group was significantly higher than those of chemotherapy group and radiotherapy group (P < 0.05).

    Conclusion 

    The patients with stageⅠb2 andⅡa2 cervical cancer in three groups have similar survival condition and postoperative complications. However, concurrent chemoradiotherapy combined with radical surgery could reduce the surgical trauma, local postoperative invasion and lymph node metastasis rate.

  • [1]
    He L, Wu L, Su G, et al. The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer[J]. Gynecol Oncol, 2014, 134(2): 419-425. doi: 10.1016/j.ygyno.2014.06.001
    [2]
    Aggarwal U, Goyal AK, Rath G. Development and characterization of the cisplatin loaded nanofibers for the treatment of cervical cancer[J]. Mater Sci Eng C Mater Biol Appl, 2017, 75(4): 125-132. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=3e0184e5c91e207f7cae7c0b59e128f6
    [3]
    Haie-Meder C, Morice P, Castiglione M, et al. Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 20 Suppl 4: 27-28. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_ae9536ac3d07c27473992a5c299efa72
    [4]
    Landoni F, Colombo A, Milani R, et al. Randomized study between radical surgery and radiotherapy for the treatment of stage ⅠB-ⅡA cervical cancer: 20-year update[J]. J Gynecol Oncol, 2017, 28(3): e34. doi: 10.3802/jgo.2017.28.e34
    [5]
    陈惠祯, 蔡红兵.现代妇科肿瘤学[M].武汉:科学技术出版社, 2006: 206-207.

    Chen HZ, Cai HB. Modern gynecological oncology[M]. Wuhan: Science and Technology Press, 2006: 206-207.
    [6]
    Mazeron R, Kamsu Kom L, Rivin del Campo E, et al. Comparison between the ICRU rectal point and modern volumetric parameters in brachytherapy for locally advanced cervical cancer[J]. Cancer Radiother, 2014, 18(3): 177-182. doi: 10.1016/j.canrad.2014.03.002
    [7]
    Benito V, Carballo S, Silva P, et al. Should the Presence of Metastatic Para-Aortic Lymph Nodes in Locally Advanced Cervical Cancer Lead to More Aggressive Treatment Strategies? [J]. J Minim Invasive Gynecol, 2017, 24(4) : 609-616. doi: 10.1016/j.jmig.2017.01.016
    [8]
    Sabour S. Prediction of rehabilitation needs after treatment of cervical cancer: a methodological mistake[J]. Support Care Cancer, 2017, 25(7): 2041. doi: 10.1007/s00520-017-3711-y
    [9]
    Wei LC, Wang N, Shi M, et al. Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma[J]. Oncol Targets Ther, 2013, 6: 67-74. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000002238676
    [10]
    Hansen H, Hogdall C, Engelholm S. Radiation therapy without cisplatin for elderly cervical cancer patients[J]. Int J Radiat Oncol Biol Phys, 2014, 90(1Suppl): S484-S485. http://www.sciencedirect.com/science/article/pii/s0360301614021506
    [11]
    Jia MX, Zhang X, Yin C, et al. Peripheral dose measurements in cervical cancer radiotherapy: a comparison of volumetric modulated arc therapy and step-and-shoot IMRT techniques[J]. Radiat Oncol, 2014, 9: 61. doi: 10.1186/1748-717X-9-61
    [12]
    Zhang G, He F, Fu C, et al. Definitive extended field intensity-modulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of ⅠB2-ⅢB cervical cancer[J]. J Gynecol Oncol, 2014, 25(1): 14-21. doi: 10.3802/jgo.2014.25.1.14
    [13]
    Fu ZZ, Li K, Peng Y, et al. Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis[J]. Medicine(Baltimore), 2017, 96(2): e5853. http://www.ncbi.nlm.nih.gov/pubmed/28079819
    [14]
    Zhang Q, Li W, Kanis MJ, et al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(28): 46580-46592. http://europepmc.org/articles/PMC5542294/
    [15]
    Fu JH, Gao Z, Ren CC, et al. Comparison of Clinical Efficacy of Three Different Neoadjuvant Approaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with StageⅠb2 and Ⅱa2 Cervical Cancer[J]. Asian Pac J Cancer Prev, 2013, 14(4): 2377-2381. doi: 10.7314/APJCP.2013.14.4.2377
    [16]
    Vizza E, Corrado G, Zanagnolo V, et al. Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study[J]. Gynecol Oncol, 2014, 133(2): 180-185. doi: 10.1016/j.ygyno.2014.02.035
  • Related Articles

    [1]TIAN Tian, TANG Sudan. Association Between Platelet Lymphocyte Ratio and Prognosis of Non-small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitor: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 611-616. DOI: 10.3971/j.issn.1000-8578.2021.20.1052
    [2]WEI Xueling, LAN Mei, PENG Xinhao, ZHANG Hanyi, LONG En, LIU Hui, LANG Jinyi. Correlation Between Immune Function Status and EBV DNA in Patients with Nasopharyngeal Carcinoma and Their Influence on Prognosis[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 600-606. DOI: 10.3971/j.issn.1000-8578.2021.20.1402
    [3]Yeerhanati·Hudusi, Aerhengbieke·Tuhanbai, Aikebaier·Younusi. Relation Between NLR, LMR, PLR and Prognosis of Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 381-386. DOI: 10.3971/j.issn.1000-8578.2021.20.0895
    [4]XU Liang, ZHANG Baihong. Prognostic Value of Lymphocyte-associated Inflammatory Markers in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 936-941. DOI: 10.3971/j.issn.1000-8578.2020.20.1179
    [5]YAO Zhiqiang, ZHANG Xiangxiang, CHEN Chaohu, CAO Jinlong, HAN Dali, LI Pan, DONG Zhichun, TIAN Junqiang. Prognostive Value of Preoperative Fibrinogen Combined with Platelet-lymphocyte Ratio on Prognosis of Patients Undergoing Radical Cystectomy[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 834-838. DOI: 10.3971/j.issn.1000-8578.2020.19.1631
    [6]FU Yali, MEI Shiwen, WEI Xing, LUO Chenghua, LIN Li, LIANG Jun. Neutrophil to Lymphocyte Ratio in Retroperitoneal Liposarcoma and Other Prognostic Factors[J]. Cancer Research on Prevention and Treatment, 2019, 46(2): 127-130. DOI: 10.3971/j.issn.1000-8578.2019.18.1096
    [7]TANG Hong, WU Weili, JIN Feng, LONG Jinhua, LI Yuanyuan, LUO Xiuling, GONG Xiuyun, CHEN Xiaoxiao, ZHANG Mang, YANG Chunli. Relationship of Peripheral Blood Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio with Curative Effect and Prognosis of Patients with Locally Advanced Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2019, 46(1): 32-36. DOI: 10.3971/j.issn.1000-8578.2019.18.0578
    [8]ZHANG Tingting, WANG Xiangyi, GUO Ziwei, DING Xiaosheng, LIANG Jun. Prognostic Significance of Platelet-lymphocyte Ratio in Hepatocellular Carcinoma Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 775-780. DOI: 10.3971/j.issn.1000-8578.2018.18.0151
    [9]HU Gen, LI Wei, SHAO Guoyi, ZHANG Xian. Predictive Effect of Preoperative Platelet-lymphocyte Ratio on Prognosis of Patients with Gastric Stromal Tumor[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 479-482. DOI: 10.3971/j.issn.1000-8578.2018.17.1428
    [10]ZHANG Sisi, YUAN Lei. Preoperative Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio for Predicting Prognosis of Esophageal Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 811-815. DOI: 10.3971/j.issn.1000-8578.2017.17.0547

Catalog

    Article views (1400) PDF downloads (324) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return